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A	protein	corona-enabled	blood	test	for	early	cancer	detection	
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Pancreatic	cancer	is	a	very	aggressive	malignancy	that	is	often	diagnosed	in	advanced	stage	with	the	implication	that	long-
term	survivors	are	extremely	rare.	Thus,	developing	new	methods	for	pancreatic	cancer	early	detection	is	an	urgent	task	of	
current	research.	To	date,	nanotechnology	offers	unprecedented	opportunities	for	cancer	therapeutics	and	diagnosis.	The	
aim	of	this	study	was	the	development	of	a	new	pancreatic	cancer	diagnostic	technology	based	on	the	exploitation	of	the	
nano-bio-interactions	between	nanoparticles	and	blood	samples.	Here	blood	samples	from	10	pancreatic	cancer	patients	
and	5	patients	without	malignancy	were	 let	 to	 interact	with	designed	 lipid	nanoparticles	 leading	 to	 formation	of	a	hard	
“protein	corona”	at	the	nanoparticle	surface.	After	isolation,	the	protein	patterns	were	characterized	by	sodium	dodecyl	
sulphate	polyAcrylamide	gel	electrophoresis	(SDS	PAGE).	We	found	that	the	protein	corona	of	pancreatic	cancer	patients	
was	 much	 more	 enriched	 than	 that	 of	 healthy	 individuals.	 Statistical	 analysis	 of	 SDS-PAGE	 results	 allowed	 us	 to	
discriminate	 between	 healthy	 and	 pancreatic	 cancer	 patients	 with	 a	 total	 discriminate	 correctness	 rate	 of	 93%.
Introduction	
Despite	recent	advances	in	molecular	diagnostics,	noninvasive	
screening	 tests	 for	 early	 stage	 tumor	 detection	 are	 almost	
nonexistent	for	most	cancer	types.	Furthermore,	no	validated	
screening	 tools	 are	 available	 for	 several	 neoplasms;	 among	
these,	 pancreatic	 cancer	 is	 a	 very	 lethal	 tumor	 with	 high	
mortality	within	a	year	after	diagnosis	and	a	median	survival	of	
less	than	six	months	1.	Five-years	survival	rates	of	15-20%	are	
reported	 when	 radical	 surgical	 resection	 is	 performed.	
Unfortunately,	at	moment	of	diagnosis,	surgery	is	feasible	only	
in	 20%	 of	 patients.	 Surgical	 approach	 is	 precluded	 to	 80%	 of	
patients,	 due	 to	 the	 presence	 of	 local	 invasion	 of	 vascular	
structures	 or	 for	 distant	 metastases.	 Avoiding	 delayed	
diagnosis	 is	 demanding.	 However,	 asymptomatic	 nature,	
absence	 of	 non-invasive	 imaging	 diagnostic	 tools,	 lack	 of	 any	
sensitive	and	specific	biomarker	make	pancreatic	cancer	early	
diagnosis	 challenging.	Moreover,	 tumor	 complex	 biology	 and	
its	 impenetrable	 architecture	 represent	 a	 hard	 basis	 to	
develop	an	effective	treatment	in	advanced	stages	in	order	to	
improve	 outcomes	 2,	 3.	 Pancreatic	 intraepithelial	 neoplasia	
(PanIN)	 lesions,	 several	 intraductal	 papillary	 mucinous	
neoplasms	(IPMN)	and	mucinous	cystic	neoplasms	(MCN)	have	
been	 identified	 as	 pancreatic	 cancer	 precursors	 4,	 but,	 their	
diagnosis	 is	 often	 challenging	 for	 both	 radiologists	 and	
endoscopists.	 Moreover,	 chronic	 pancreatitis	 can	 lead	 to	
pancreatic	 neoplasms	 and	 cyto-histological	 analysis	 can	 be	
unsatisfying	 5.	 To	 date,	 a	 non-biopsy-based-test	 detecting	
serum	 carbohydrate	 antigen	 19-9	 (CA19-9)	 is	 routinely	 used.	
However,	 this	 approach	 fails	 to	 be	 specific	 and	 is	 poorly	
sensitive.	 Therefore,	 it	 becomes	 a	 priority	 to	 develop	 more	
specific	 and	 sensitive	 diagnostic	 tests.	 In	 this	 field,	 recently	
Melo	 et	 al.	 detected	 and	 isolated	 pancreatic	 cancer-cell-
derived	 exosomes	 circulating	 in	 blood	 and,	 through	 mass	
spectrometry	 analysis,	 identified	 a	 cell	 surface	 proteoglycan,	
glipican-1	(GPC1+),	specifically	enriched	on	cancer-cell-derived	
exosomes	 6.	 GPC1+	 exosomes	 were	 detected	 in	 serum	 of	
pancreatic	 cancer	 patients	 allowing	 to	 distinguish	 healthy	
subjects	 and	 patients	 with	 benign	 pancreatic	 disease	 from	
those	 with	 early-and	 late-stage	 pancreatic	 cancer.	 	 More	
recently,	 Xie	 et	 al.	 identified	 two	 long	 non-coding	 RNAs	
(lncRNAs)	in	pancreatic	cancer	patients’	saliva.	They	found	that	
salivary	 levels	of	HOTAIR	and	PVT1	 lncRNAs	were	significantly	
higher	in	pancreatic	cancer	patients	compared	to	healthy	ones	
7.	Using	quantitative	PCR	(qPCR),	they	demonstrated	that	both	
salivary	lncRNAs	discriminated	pancreatic	cancer	patients	from	
healthy	 controls	 and	 benign	 pancreatic	 lesions	 patients	 with	
sensibility	 ranging	 from	 60	 to	 97%.	 However,	 despite	 being	
promising,	 the	 above-mentioned	 methods	 depend	 on	
numerous	 and	 laborious	 steps	 (i.e.	 exosome	 isolation,	
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Figure	1.	(A)	When	nanoparticles	come	into	contact	with	physiological	environments	(e.g.	blood,	interstitial	fluids	etc.)	they	are	immediately	surrounded	by	proteins	
forming	a	long-standing	coating	referred	to	as	protein	corona.	(B)	Following	exposure	to	blood	samples,	the	protein	corona	works	as	a	“nano-accumulator”	and	allows	
detecting	 alterations	 in	 circulating	 proteins	 as	 those	 occurring	 in	 cancer.	 Are	 the	 protein	 coronas	 formed	 upon	 interaction	with	 the	 blood	 of	 pancreatic	 cancer	
patients	and	healthy	volunteers	equal	to	each	other?	This	is	a	key	question	towards	bringing	the	protein	corona	from	preclinical	studies	to	the	clinic.	
identification	 of	 cell	 surface	 proteoglycan	 using	 mass	
spectroscopy	or	immunogold-TEM	and	qPCR).	Nonetheless,	
they	 are	 extremely	 expensive	 and	 time	 consuming	 thus	
being	 not	 appropriate	 for	 early	 cancer	 detection.	 As	 a	
consequence,	the	development	of	fast,	cheap,	user-friendly	
and	non-invasive	 tools	 for	 pancreas	 cancer	 early	 diagnosis	
is	needed.	Recent	advance	 in	nanotechnology	has	brought	
many	 innovative	 approaches	 and	 solutions	 to	 biomedical	
research.	Due	 to	 the	peculiar	properties	 that	arise	when	a	
material	 is	 reduced	 to	 the	 nanoscale	 (1-100	 nm),	
nanomaterials	 in	 general	 and	 nanoparticles	 (NPs)	 in	
particular	are	being	utilized	in	almost	limitless	applications.	
When	 NPs	 are	 dispersed	 in	 a	 biological	 fluid,	 they	
encounter	 an	 immediate	 and	 dramatic	 challenge	 of	 their	
“synthetic	 identity”	 8,	 as	 a	 consequence	 of	 the	
establishment	 of	 chemical–physical	 interactions	 between	
the	NP	surface	and	medium	components.	The	result	 is	 the	
development	of	 a	new	 interface	onto	NPs	 surface,	 the	 so-
called	 “bio–nano	 interface”,	 composed	 by	 biomolecules	
such	as	proteins,	sugars	and	lipids.	This	biomolecular	shell	is	
dynamic	by	nature	and,	given	the	protein	enrichment,	 it	 is	
usually	referred	to	as	protein	corona	(PC)	9.	Comparably	to	
the	 atmosphere	 of	 the	 Sun,	 named	 the	 solar	 corona,	
proteins	are	supposed	to	establish	a	dynamic	 layer	around	
NPs;	 hence,	 the	 phenomenon	 was	 nicknamed	 “protein	
corona”	 9,	 10.	 It	 is	 made	 of	 two	 components,	 the	 ‘hard’	
corona	 (HC)	 and	 the	 ‘soft’	 corona	 (SC).	 HC	 is	 made	 of	
proteins	strongly	adsorbed	to	the	bare	NP	surface,	while	SC	
is	composed	of	proteins	with	an	affinity	for	the	HC	itself	and	
in	 rapid	 exchange	with	 the	 surrounding	 environment.	 The	
long-standing	HC	 is	 the	 interface	 “seen”	and	processed	by	
living	 systems,	 thus	 it	 influences	 various	 biological	
responses,	 such	 as	 pharmacological	 and	 toxicological	
effects	11,	12.	Nowadays,	it	is	well	recognized	that	formation	
and	 composition	 of	 HC	 depends	 on	 several	 factors	 13-21:	 i)	
surface	 properties	 of	 NPs	 (i.e.	 size,	 shape,	 curvature,	
surface	chemistry	and	surface	charge);	 ii)	characteristics	of	
biological	 media	 including	 protein	 concentration,	 protein	
source,	and	 temperature;	 iii)	 incubation	 time.	Because	 the	
protein	pattern	 in	 cancer	 patients’	 blood	differs	 from	 that	
of	healthy	donors,	the	molecular	composition	of	HC	formed	
around	NPs	 could	 change	between	 cancer	 and	non-cancer	
patients	 blood.	 These	 alterations	 are	 often	 small	 and	
difficult	to	be	detected	by	conventional	blood	analyses.	On	
the	 other	 side,	 the	 HC	 acts	 as	 a	 “nano-concentrator”	 of	
those	 serum	proteins	with	 affinity	 for	 the	NP	 surface.	 The	
most	 relevant	 implication	 is	 that	 thoroughly	
characterization	of	HC	could	allow	detecting	minor	changes	
in	protein	concentration	at	the	very	early	stages	of	disease	
development	 or	 even	 after	 chemotherapy	 or	 surgery,	 i.e.	
when	alteration	in	circulating	level	of	proteins	could	not	be	
diagnosed	 if	 investigated	 by	 blood	 tests.	 In	 this	 work,	 we	
explored	the	feasibility	of	developing	a	novel	technology	for	
pancreatic	cancer	detection	based	on	the	recently	reported	
differences	in	the	HC	formed	onto	lipid	NPs	after	exposure	
to	pancreatic	cancer	and	non-cancer	blood	serum	samples	
22	 (Figure	 1).	 To	 this	 end,	 we	 employed	 a	 liposomal	
formulation	 made	 of	 a	 lipid	 composition	 made	 of	 HSPC	
(hydrogenated	soy	phosphatidylcholine),		
Cholesterol	 (Chol)	 and	 DSPG	 (1,2-distearoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)])	that	is	the	basis	of	the	liposomal	
amphotericin	 B.	 Notably,	 we	 found	 that	 the	 HCs	 varied	
between	 pancreatic	 cancer	 and	 healthy	 human	 blood.	 On	
the	 other	 side,	 common	 blood	 tests	 did	 not	 allow	
discriminating	 blood	 samples.	 Our	 results	 show	 that	
emerging	HC-based	 technologies	 could	open	new	horizons	
towards	pancreatic	cancer	early	diagnosis.		
Results	and	Discussion		
Following	1-hour	exposure	to	HP	of	healthy	volunteers,	HCs	
were	 detached	 from	 NP	 surface	 and	 analyzed	 by	 1D	
SDS/PAGE.	We	observed	that:	 (i)	 four	major	protein	bands	
located	 at	 ≈	 110	 kDa,	 90	 kDa,	 75	 kDa	 and	 37	 kDa	 are	 in	
common	 for	various	healthy	cases	 (not	 reported	 for	 space	
consideration);	 (ii)	 the	 intensity	 of	 the	 same	 protein	 band	
from	 different	 healthy	 cases	 varies.	 Collectively,	 these	
findings	 indicate	 that	 the	HCs	 formed	 in	 the	HP	of	healthy	
subjects	are	similar	to	each	other.	The	observed	changes	in	
protein	band	intensities	likely	arise	from	plasma	alterations	
occurring	among	healthy	people	due	to	several	factors	such	
as	genetic	background,	 life	style	and	geographical	origin.	 It	
is	known	that	circulating	levels	of	proteins	can	be	altered	by	
clinical	manifestations.	 Anyway,	 no	 protein	 biomarker	 has	
been	 clinically	 validated	 to	 diagnose	 pancreatic	 cancer	 so	
far.	Carcinoembryonic	antigen	(CEA)	has	been	proposed	as	
potential	biomarker	of	pancreatic	cancer,	but	the	protein	is	
not	 produced	 by	 all	 pancreatic	 tumours	 and	 has	 lower	
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sensitivity	 than	 CA19-9.	 On	 the	 other	 side,	 the	 HC	 of	 NPs	
could	 work	 as	 a	 “nano-concentrator”	 of	 those	 serum	
proteins	with	affinity	for	the	bare	NP	surface.	Some	of	them	
could	 be	 simultaneously	 altered	 by	 cancer	 not	 only	 in	
concentration,	 but	 also	 in	 their	 structure	 and	 function.	
Slight	 protein	 changes	 (i.e.	 not	 detectable	 by	 routinely	
blood	 tests)	 could	 have	 a	 deep	 impact	 on	 both	
nanoparticle-protein	 and	 protein-protein	 interactions	
within	 HC.	 As	 a	 result	 of	 such	 global	 change,	 exposure	 of	
NPs	 to	 HP	 from	 pancreatic	 cancer	 patients	 could	 lead	 to	
modified	HCs.	 Present	 exploration	was	 therefore	 aimed	at	
establishing	whether	exposure	of	NPs	 to	HP	 samples	 from	
healthy	 versus	 cancer	 patients	 may	 result	 in	 significant	
modifications	of	 the	HC.	1D	SDS/PAGE	was	 therefore	used	
to	 analyse	 the	 protein	 patterns	 of	 the	 HC	 of	 pancreatic	
cancer	patients.		
By	visual	inspection,	the	same	four	protein	bands	identified	
for	 healthy	 individuals	 (≈	 110	 kDa,	 90	 kDa,	 75	 kDa	 and	37	
kDa)	 dominated	 the	 protein	 patterns	 of	 pancreatic	 cancer	
patients.	 A	 densitometry	 analysis	 of	 electrophoretic	 gels	
was	 performed	 for	 quantitative	 comparison.	 As	 clearly	
shows,	the	protein	bands	are	much	more	intense	in	the	HC	
of	 pancreatic	 cancer	 patients	 than	 in	 that	 of	 healthy	
volunteers.	 As	 the	 band	 intensity	 does	 correlate	 with	
protein	binding,	 results	 of	 Figure	2	 suggest	 that	 the	HC	of	
pancreatic	 cancer	 patients	 is	 more	 enriched	 than	 that	 of	
control	subjects.		
However,	the	great	variability	between	both	groups	makes	
band	 intensity	 alone	 not	 enough	 to	 discriminate	 between	
cancer	patients	and	healthy	subjects.	To	properly	evaluate	
changes	in	the	HC,	PCA	was	performed.	As	Figure	3A	clearly	
shows,	 pancreatic	 cancer	 patients	 and	 healthy	 ones	 were	
strongly	separated	in	the	PC1-PC2	plane.	This	result	clearly	
demonstrates	that	the	PCA	performed	using	the	intensities	
of	 four	 selected	 protein	 bands	 is	 a	 powerful	 tool	 to	
discriminate	 between	 the	 two	 groups.	 To	 provide	 a	
quantitative	 estimation	 of	 group	 separation,	 LDA	 on	 PCs	
was	accomplished.	In	Figure	3B	we	report	the	PC	centroids	
of	the	two	groups	and	the	linear	discriminant	function	that	
splits	 the	 PCs	 Cartesian	 plane	 in	 two	 prediction	 regions.	
Notably,	 statistical	 analysis	 on	 the	 intensity	 of	 the	 four	
major	 bands	 found	 in	 coronas’	 protein	 patterns	 identified	
correctly	 9	 of	 10	 cancer	 patients	 and	 5	 of	 5	 healthy	
subjects.	The	test	with	90%	specificity	and	100%	sensitivity	
in	distinguishing	healthy	 control	 from	cancer	 case	 reached	
an	 overall	 correctness	 of	 93%	 (Table	 S2).	 To	 compare	 the	
prediction	 ability	 of	 the	 particle-enabled	 technology	 with	
that	feasible	by	means	of	routinely	blood	test,	PCA	and	LDA	
were	replicated	using	the	24	haematological	values	as	input	
parameters	(Table	S3).	As	panels	C	and	D	of	Figure	3	clearly	
show,	samples	centroids	were	almost	super-imposed	in	the	
PCs	 Cartesian	 plane.	 Our	 findings	 imply	 that	 statistical	
analysis	applied	to	the	results	of	blood	tests	does	not	allow	
to	accurately	distinguishing	cancer	vs.	non-cancer	patients.	
We	 underline	 that	 conclusions	 of	 our	 study	 are	 far	 from	
being	general	due	to	the	small	number	of	samples.	Moving	
from	descriptive	 to	predictive	modelling	will	 require	 larger	
series	of	experiments.	However,	our	findings	represent	the	
proof	 of	 concept	 that	 the	 protein	 corona	 technology	 is	 a	
promising	 tool	 for	 the	 early	 diagnosis	 of	 pathological	
conditions	 where	 alterations	 of	 circulating	 proteins	 occur.	
Implications	 could	 be	 extremely	 relevant	 in	 pancreatic	
cancer,	wherein	early	diagnosis	is	the	only	change	of	access	
to	 treatment	 with	 curative	 intent.	 In	 the	 next	 future,	
nanotechnological	 solutions	 based	 on	 the	 exploitation	 of	
the	 protein	 corona	 will	 open	 new	 horizons	 for	 clinical	
diagnosis.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.	 Major	 proteins	 bands	 (110	 kDa,	 90	 kDa,	 75	 kDa	 and	 37	 kDa)	
identified	 in	 the	 protein	 coronas	 of	 lipid	 nanoparticles	 after	 exposure	 to	
human	 plasma	 of	 pancreatic	 cancer	 (P,	 blue	 bars)	 and	 healthy	 (H,	 orange	
bars)	patients.	Results	are	the	average	of	three	independent	measurements	
standard	deviation.			
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.	(A)	Principal	components	(PC1,	PC2)	calculated	from	the	set	of	the	
four	protein	bands	reported	in	Figure	2.	Blue	and	orange	circles	refer	to	the	
pancreatic	 cancer	 and	 healthy	 patients	 respectively.	 (B)	 Centroids	 of	 the	
distributions	 of	 panel	 A.	 The	 straight	 line	 separates	 the	 healthy	 volunteers	
group	from	pancreatic	cancer	patients	group	according	to	the	results	of	the	
linear	 discriminant	 analysis	 (LDA).	 (C)	 Principal	 components	 (PC1,	 PC2)	
calculated	using	 the	set	of	24	hematological	values	 reported	 in	Table	S3	as	
input	parameters.	(D)	Centroids	of	the	two	distributions	reported	in	panel	C	
are	almost	superimposed.		
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Materials	and	Methods		
Demographic	characteristics	and	clinical	laboratory	tests	
Blood	 samples	 from	 10	 consecutive	 histologically	 proven	
pancreatic	 adenocarcinoma	 (median	 age	 72	 years)	 and	
from	a	group	of	5	patients	 (median	age	66	years)	affected	
by	surgical	benign	diseases	that	met	the	criteria	reported	in	
Table	 S1	 have	 been	 collected.	 In	 the	 present	 manuscript,	
the	 last	group	of	patients	are	 considered	 ‘healthy”	as	well	
as	their	group.	“Healthy”	mean	that	they	were	not	affected	
by	 malignancies	 and	 represent	 the	 control	 group.	 Data	
regarding	medical	history	and	clinical-instrumental	work-up	
have	 been	 assessed	 for	 each	 patient;	 particularly,	 total	
protein,	 serum	albumin	and	serum	protein	electrophoresis	
have	 been	 considered	 in	 both	 groups.	 Total	 protein	 and	
albumin	were	dosed	on	Dimension	Vista	(Siemens)	system.	
Obtained	values	are	expressed	in	g/dl	for	both	albumin	and	
total	 protein.	 Electrophoresis	 has	 been	 performed	 on	
Capillarys	 Sebia	 electrophoresis	 system	 for	 half	 an	 hour	
(zonal	 electrophoresis	 in	 liquid	 phase).	 It	 is	 a	 semi-
quantitative	analysis	and	values	of	various	protein	fractions	
α1	 (e.g.	 anti-trypsin),	 α2	 globulin	 (e.g.	 α2-macroglobulin,	
aptoglobine,	ceruloplasmine),		β1	globulin	(e.g.	transferrin),		
β2	 globulin	 (e.g.	 β	 2-microglobulin),	 	 γ	 globulin	 (e.g.	
immunoglobulin))	 are	 expressed	 as	 percentage	 intervals.	
For	 patients	 in	 pancreatic	 cancer	 group,	 CEA	 and	 Ca	 19.9	
have	 been	 evaluated	 too.	 Blood	 collection	 and	 plasma	
preparation	and	storage	have	been	performed	according	to	
methods	 already	 described	 23.	 According	 to	 their	 clinical	
stage,	 pancreatic	 cancer	 patients	 underwent	 surgery,	
neoadjuvant	 chemo-radiotherapy	 or	 chemotherapy.	 For	
surgical	 resected	 patients,	 pathological	 staging	 data	 have	
been	 collected.	 Clinical	 and	 pathological	 stages	 are	
reported	 according	 to	 TNM	 staging	 system	 24.	 The	 Ethical	
Committee	 of	 University	 “Campus	 Bio-Medico	 di	 Roma”	
approved	 the	 present	 study.	 Tables	 S4-S6	 show	
demographic	and	clinical	characteristics	of	our	series.	
Liposomes	preparation	
Hydrogenated	 soy	 phosphatidylcholine	 (HSPC),	 1,2-
distearoyl-sn-glycero-3-[Phospho-rac-(1-glycerol)]	 (Sodium	
Salt)	 (DSPG)	 were	 purchased	 from	 Avanti	 Polar	 Lipids	
(Alabaster,	 AL)	 Cholesterol	 (Chol)	 were	 purchased	 from	
Sigma-Aldrich	(Milan,	Italy).	Ambisome-like	liposomes	were	
synthesized	 according	 to	 standard	 protocols	 at	 the	 molar	
ratios	 HSPC:DSPG:Chol	 (2.5:1:1.2)	 25.	 Lipid	 films	 were	
hydrated	 with	 phosphate	 saline	 buffer	 (PBS)	 10	 mmol/l	
(pH=	 7.4)	 to	 a	 final	 lipid	 concentration	 1	 mg/mL.	 The	
obtained	 liposome	 suspension	 was	 extruded	 20	 times	
through	a	0.05	µm	polycarbonate	carbonate	filter	with	the	
Avanti	 Mini-Extruder	 (Avanti	 Polar	 Lipids,	 Alabaster,	 AL).	
Liposomes	were	 small	 in	 size	 (particle	 diameter	 ≈	 130	 ±	 5	
nm)	and	negatively	charged	(surface	charge	≈	-	30	±	3	mV).	
Measurements	of	size	and	surface	charge	were	performed	
at	 room	 temperature	 on	 a	 Zetasizer	 Nano	 ZS90	 (Malvern,	
UK)	 equipped	 with	 a	 5	 mW	 HeNe	 laser	 (wavelength	 λ=	
632.8	 nm)	 and	 a	 digital	 logarithmic	 correlator.	 More	
detailed	information	can	be	found	elsewhere	26.	
Liposome-protein	complexes	
Liposome-protein	 complexes	were	 prepared	 by	 incubating	
liposomes	 with	 HP	 (1:1	 v/v)	 at	 37	 °C	 for	 1-hour.	
Experimental	 conditions	 (i.e.	 plasma	 concentration,	
temperature	 and	 incubation	 time)	 were	 chosen	 according	
to	 previous	 investigations	 26-29	 After	 incubation,	 liposome-
protein	 complexes	 were	 isolated	 by	 centrifugation	 for	 15	
min	at	14,000	 rpm.	Then	pellets	were	washed	 three	 times	
with	PBS	to	remove	unbound	proteins	obtaining	the	“hard	
corona.”		
1D-SDS-PAGE	experiments	
The	hard	corona-coated	NPs	were	re-suspended	in	20	μl	of	
Laemmli	 Loading	 buffer	 1X	 (10	 μl	 βME/1	 ml	 Laemmli	
Loading	 buffer)	 and	 boiled	 for	 5	 min	 at	 100	 °C.	 Identical	
volumes	(10	μl)	of	each	sample	were	 loaded	on	a	gradient	
polyacrylamide	 gel	 (4-20%	Criterion	 TGX	 precast	 gels,	 Bio-
Rad)	 and	 run	 at	 100	 V	 for	 about	 150	minutes.	 Gels	 were	
washed	 in	 double-distilled	 water	 (ddH2O)	 and	 fixed	 over	
night	 for	12	hours	 in	a	de-staining	 solution	 (MeOH	50%	 in	
ddH2O)	with	gentle	agitation	at	room	temperature,	with	at	
least	 one	 solution	 change.	 In	 order	 to	 determine	
differences	in	corona	composition,	we	stained	the	proteins	
with	 highly	 sensitive	 silver-ammonia	 solution	 for	 30	
minutes.	 Then,	 gels	 were	 rinsed	 3	 times	 in	 ddH2O,	 40	
seconds	 each	 rinse,	 then	 incubated	 with	 acidic	 developer	
solution	 from	 3	 to	 5	minutes.	 Once	 all	 the	 protein	 bands	
started	 to	clearly	appear,	developer	solution	was	 removed	
and	stop	solution	(acetic	acid	10%,	methanol	45%	in	ddH2O)	
was	added.	Pictures	of	gels	were	captured	by	KODAK	Digital	
DC120	.		
	
Statistical	analysis	
Principal	 component	 analysis	 (PCA)	 is	 a	 classical,	 well-
established	method	frequently	used	in	physical	as	well	as	in	
social	 and	 biological	 sciences	 30.	 Its	 aim	 is	 to	 project	 a	
multidimensional	 phenomenon	 onto	 a	 reduced	 set	 of	
orthogonal	 axes	 (principal	 component	 scores	 or	
eigenfunctions)	 with	 minimal	 loss	 of	 information	 31.	 The	
new	 coordinates	 are	 linear	 combinations	 of	 the	 original	
ones:	 they	 are	 orthogonal	 by	 construction,	 each	
representing	 an	 independent	 aspect	 of	 the	 data	 set.	
Moreover,	the	principal	components	are	endowed	with	the	
property	 of	 explaining	 the	 system	 variability	 in	 a	
hierarchical	 way:	 this	 implies	 that	 we	 can	 save	 the	
meaningful	(signal-like)	part	of	the	information	retained	by	
the	first	principal	components	and	discard	the	noise,	which	
is	supposed	to	concentrate	on	the	minor	components.	The	
set	 of	 original	 variables	 obtained	 under	 each	 explored	
condition	is	thus	linearly	transformed	by	the	PCA	into	a	new	
set	 of	 variables	 (called	 PC1,	 PC2,	 etc.)	 endowed	 with	 the	
property	of	being	orthogonal	to	each	other	and	ordered	by	
the	decreasing	amount	of	explained	variance	(information)	
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in	the	data.	We	took	extensive	advantage	of	 that	property	
to	 include	 within	 some	 of	 principal	 components	 a	 major	
fraction	 of	 the	 information	 present	 in	 the	 hematological	
values	describing	 the	patients’	 condition.	By	means	of	 this	
analytical	 technique,	 we	 compared	 two	 different,	 even	 if	
correlated,	 datasets.	 One	 dataset	 was	 composed	 by	 24	
different	 hematological	 parameters.	 The	 second	 dataset	
was	composed	of	4	variables,	i.e.	the	intensity	of	four	major	
bands	 identified	 in	the	patterns	of	nanoparticle-corona		by	
1D-SDS-PAGE		and	located	at	110	kDa,	90	kDa,	75	kDa	and	
37	 kDa.	 Thus,	 we	 clustered	 and	 classified	 the	 patients	 by	
means	of	 Linear	Discriminant	Analysis	 (LDA)	performed	on	
the	principal	components	32.	LDA	is	the	method	of	election	
to	 determine	 whether	 meaningful	 differences	 exist	
between	 the	 groups	 and	 to	 identify	 the	 discriminating	
power	of	each	variable	32.	The	technique	constructs	a	set	of	
linear	 functions	 of	 predictors,	 known	 as	 discriminant	
functions,	such	that	L	=	b1	x1	+	b2	x2	+	…	+	bn	xn	+	c,	where	
the	 bi	 are	 discriminant	 coefficients	 the	 xi	 are	 the	 input	
variables	or	predictors	and	c	is	a	constant.	L	is	a	class	index	
that	usually	takes	the	values	of	1	and	–1	respectively	for	the	
two	classes	to	be	discriminated,	so	that	a	positive	value	of	L	
points	 to	 class	 A	 and	 a	 negative	 value	 to	 class	 B.	 We	
performed	LDA	on	the	two	principal	components	of	the	two	
considered	datasets.			
Conclusions		
Extensive	 clinical	 investigations	 are	 necessary	 to	 validate	
the	 clinical	 applications	 of	 the	 new	 protein	 corona-based	
test,	and	rigorously	evaluate	the	factors	that	may	influence	
its	specificity	and	sensitivity.	This	would	further	validate	the	
potential	of	protein	corona	for	early	detection	of	pancreatic	
cancer	 thus	 leading	 novel	 opportunities	 in	 terms	 of	
treatment	and	outcomes.	
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